Clene's Amyotrophic Lateral Sclerosis Candidate Shows Favorable Impact On Disease Progression

Clene Inc CLNN presented new data from the RESCUE-ALS Phase 2 study of CNM-Au8, a catalytically active gold nanocrystal suspension for amyotrophic lateral sclerosis (ALS). Data were shared at the 4th Annual ALS ONE Research Symposium.

• New data presented included analyses of CNM-Au8's efficacy in limb and bulbar onset participants across critical endpoints of slowing ALS clinical worsening.
• Consistent clinical benefit was shown in both limb and bulbar onset participants for the pre-specified endpoint of ALS disease progression defined as death or the need for tracheostomy, non-invasive ventilation, or gastrostomy.
• Similarly, CNM-Au8 treated participants showed consistent clinical benefit in the proportion without a 6-point decline on the ALSFRS-R across both limb and bulbar onset participants in a post hoc analysis.
• Despite the small sample size of 45 subjects at 36 weeks, participants treated with CNM-Au8 had an improved average CAFS summated score of +4.4 compared to a -4.6 decline for the placebo group.
• The CAFS combines the change in ALS Functional score with participant survival time.
• Related: Clene's Amyotrophic Lateral Sclerosis Candidate Disappoints In Mid-Stage Study.
• Price Action: CLNN shares are up 5.45% at $6 during the market session on the last check Wednesday.